Human Immunodeficiency Viruses (HIV) Clinical Trials Market Report 2026

The human immunodeficiency viruses (hiv) clinical trials market size has grown strongly in recent years. It will grow from $1.94 billion in 2025 to $2.11 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to high global hiv disease burden, expansion of antiretroviral drug research, increased public and private funding for hiv studies, growth of clinical research infrastructure, regulatory support for hiv drug development.

The human immunodeficiency viruses (hiv) clinical trials market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing development of curative and preventive hiv therapies, rising adoption of adaptive trial designs, expansion of vaccine-focused hiv trials, growing use of ai in clinical research, increased focus on long-term safety and efficacy outcomes. Major trends in the forecast period include increasing adoption of decentralized clinical trial models, rising use of digital patient recruitment tools, growing focus on long-acting hiv therapies in trials, expansion of real-world evidence integration, enhanced use of data analytics in trial management.

The increasing incidence of human immunodeficiency virus (HIV) infections is expected to drive the growth of the HIV clinical trials market going forward. HIV infection is caused by a virus that weakens the immune system, increasing vulnerability to opportunistic infections and potentially leading to AIDS. Rising HIV incidence is linked to limited awareness, risky behaviors, and delayed testing. HIV clinical trials support affected patients by evaluating new drugs, vaccines, and treatment approaches that improve prevention, disease management, and transmission reduction. For instance, in August 2024, according to the Minority HIV/AIDS Fund (MHAF), an estimated 39.9 million people worldwide were living with HIV in 2023. Therefore, the increasing incidence of HIV infections is driving the growth of the HIV clinical trials market.

Leading companies operating in the human immunodeficiency virus (HIV) clinical trials market are focusing on developing innovative solutions such as HIV prevention injections to improve treatment effectiveness and reduce transmission rates. An HIV prevention injection is a long-acting injectable medication administered periodically to prevent HIV infection in high-risk individuals by blocking the virus from establishing infection in the body. For instance, in August 2025, Gilead Sciences Inc., a US-based pharmaceutical company, received approval from the European Union for Yeytuo (lenacapavir) for HIV treatment. It is a twice-yearly injectable HIV prevention therapy that demonstrated nearly 100% efficacy in clinical trials, significantly lowering the risk of sexually acquired HIV-1 infection. Its long-acting dosing enhances adherence and convenience compared to daily oral PrEP, addressing a key gap in HIV prevention. This treatment is intended for adults and adolescents at elevated risk and aims to expand access and reduce new HIV infections globally as part of comprehensive prevention strategies.

In July 2025, Elliott Investment Management L.P., Patient Square Capital LP, and Veritas Capital Fund Management L.L.C., all US-based investment firms, acquired Syneos Health for $7.1 billion. Through this acquisition, the investor group aims to accelerate Syneos Health’s growth, enhance service delivery, and transform the company into a technology-enabled leader in biopharmaceutical solutions. Syneos Health is a US-based pharmaceutical commercial company that provides human immunodeficiency virus (HIV) clinical trial services.

Major companies operating in the human immunodeficiency viruses (hiv) clinical trials market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co., IQVIA Holdings Inc., ICON plc, Moderna Inc., ViiV Healthcare Limited, HOOKIPA Pharma Inc., Excision BioTherapeutics Inc., American Gene Technologies International Inc., Bionor Holding AS, Aelix Therapeutics, Immuno Cure BioTech Private Limited, ImmunityBio.

North America was the largest region in the human immunodeficiency viruses (HIV) clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency viruses (hiv) clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human immunodeficiency viruses (hiv) clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the hiv clinical trials market by increasing costs of imported laboratory equipment, diagnostic kits, reagents, data management systems, and trial monitoring technologies. Research institutions and pharmaceutical companies in North America and Europe are most affected due to reliance on imported research tools, while Asia-Pacific faces cost pressures in trial execution and material sourcing. These tariffs are increasing overall trial costs and extending timelines. However, they are also encouraging local sourcing of research materials, regional trial infrastructure development, and investment in domestically produced clinical research technologies.

The human immunodeficiency viruses (hiv) clinical trials market research report is one of a series of new reports that provides human immunodeficiency viruses (hiv) clinical trials market statistics, including human immunodeficiency viruses (hiv) clinical trials industry global market size, regional shares, competitors with a human immunodeficiency viruses (hiv) clinical trials market share, detailed human immunodeficiency viruses (hiv) clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the human immunodeficiency viruses (hiv) clinical trials industry. This human immunodeficiency viruses (hiv) clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Human immunodeficiency virus (HIV) clinical trials are research studies conducted on human participants to assess the safety, effectiveness, and potential outcomes of new drugs, therapies, vaccines, or treatment strategies intended to prevent, manage, or cure HIV infection. These trials progress through structured phases, ranging from early safety assessments to large-scale effectiveness evaluations, and provide the clinical evidence required for regulatory approval and enhanced patient care.

The primary phases of human immunodeficiency virus (HIV) clinical trials are phase I, phase II, phase III, phase IV, and preclinical. Phase I represents the initial testing stage conducted on a small group of healthy volunteers or patients. These trials assess drug categories such as antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), long-acting injectable antiretrovirals, and experimental drugs, using study designs including interventional studies, observational studies, and expanded access studies. Targeted patient populations include adults, pediatric patients, seniors, pregnant women, and high-risk groups, with results utilized by end-users such as pharmaceutical companies, research institutes, hospitals, and others.

The human immunodeficiency virus (HIV) clinical trials market includes revenues earned by entities by providing services such as clinical study design and protocol development, patient recruitment and screening, and medical monitoring and care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.